ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Zacks Small Cap Research on MSN30m
MIRA Makes Another Pain Management StrideMIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback